Pipeline        AIM Biologicals         Macimorelin Tx         AEZS-150         Macimorelin Dx         Oral Coronavirus Vaccine

Macimorelin Therapeutic
Macimorelin as a Potential Therapeutic for Amyotrophic
Lateral Sclerosis (ALS, Lou Gehrig's disease)

Asset%206_edited.png
ALS Ribbon.png

Entered Material Transfer Agreement (MTA)
with University
of Queensland
in January 2021

Exclusive rights for AEZS to negotiate a license agreement for the commercial use of the results

University researchers to secure grants and conduct preclinical and clinical studies

 

AEZS as co-investigator providing medication as well as preclinical and clinical know-how

Investigation as a potential
treatment for Amyotrophic Lateral Sclerosis (ALS,
Lou Gehrig's disease)

 

Neurodegenerative

motor neuron disease (MND)

with significant unmet medical need

+Our

Pipeline